Mechanistic Rationale for Structured Supplement Sequencing as a Cohort-Split Variable in the Proposed IMIG Clinical Trial for Immune-Derived Autism
Important: This document presents a mechanistic hypothesis for scientific discussion and collaborative trial design evaluation. It does not constitute medical advice, a treatment protocol, or a clinical recommendation. All therapeutic decisions must be made by licensed clinicians with direct knowledge of the patient. The adjunct protocol described here has not been evaluated in a controlled clinical trial. Evidence levels are explicitly assigned to each mechanistic claim throughout the document.
The proposed IMIG trial for immune-derived autism (IDA) tests whether biomarker-guided immunoglobulin therapy can restore neuropeptide cascade function in a defined subgroup of autism spectrum disorder. This question is well-framed and the primary endpoint is appropriate. The trial design question addressed in this document is a secondary one: does the metabolic and signaling infrastructure of SST-14 interneurons — their NAD⁺ substrate, their adenylyl cyclase responsiveness, the SASP cytokine burden suppressing their promoter activity — limit IMIG efficacy in a way that a concurrent adjunct protocol could measurably improve?
The answer matters because IMIG's mechanism is upstream. It removes the immune activation driving the suppression cascade. But SST-14 interneurons that have been running in a NAD⁺-depleted, adenylyl cyclase-suppressed, SASP-burdened state for years cannot immediately resume tonic firing simply because the upstream immune brake is released. The adjunct protocol is designed to build the metabolic floor that IMIG requires to be maximally effective — ensuring that when IMIG begins removing the transcriptional ceiling, the cellular machinery beneath it is capable of responding.
A cohort split — IMIG alone versus IMIG plus adjunct protocol — directly tests this hypothesis while adding no additional risk to the primary endpoint. Both cohorts receive IMIG. The question is whether the adjunct compounds produce a measurably superior response trajectory on the same biomarker endpoints. A positive result establishes the first evidence base for the adjunct protocol as a structured intervention. A negative result establishes that upstream immune clearance is the rate-limiting step. Either result advances the field. See Section 10 for the full proposed design.
The biological cascade leading to SST-14 silencing originates in gut pH dysregulation. Multiple common environmental insults converge on this step simultaneously: cesarean delivery bypassing maternal microbial seeding; formula feeding eliminating colostrum immunoglobulins; antibiotic exposure disrupting commensal colonization; acetaminophen depleting glutathione in children with compromised transsulfuration pathways; glyphosate depleting Lactobacillus and Bifidobacterium while sparing LPS-producing gram-negative species; mercury binding directly to the CD26 receptor site blocking adenosine deaminase; and organophosphate pesticide exposure producing muscarinic receptor downregulation.
Elevated gut pH above 4.0 disables pepsin-mediated proline bond cleavage. Intact casomorphin and gliadorphin fragments — opioid peptides from incompletely digested casein and gluten — accumulate and initiate two parallel suppression cascades operating simultaneously.
| Mechanism | Pathway | Driver |
|---|---|---|
| Mechanism 1 — NF-κB/CREB Competition | Pro-inflammatory cytokines activate NF-κB on SST-14 interneurons. NF-κB competes with phosphorylated CREB for occupancy of the CRE binding site on the somatostatin gene promoter, and NF-κB and CREB additionally compete for limiting amounts of the coactivator CBP/p300. With NF-κB occupying the promoter and sequestering CBP, no amount of cAMP-PKA activation can drive SST-14 transcription. | Chronic cytokine load from LPS translocation, IDO1 activation, and microglial M1 polarization. |
| Mechanism 2 — Gi-Coupled Adenylyl Cyclase Suppression (Two Independent Inputs) | Input A — Adenosine: accumulated adenosine from CD26/DPP-IV impairment and NAD⁺ consumption by CD38 activates inhibitory Gi-coupled A1/A2A receptors, suppressing adenylyl cyclase. Input B — Mu-opioid: casomorphin and gliadorphin activate Gi-coupled mu-opioid receptors (EC50 ~30 nM for DAMGO; 25–60% adenylyl cyclase inhibition), providing a second independent Gi-mediated suppression of adenylyl cyclase operating in parallel with adenosine. Without adenylyl cyclase activity, cAMP cannot be produced, PKA cannot phosphorylate CREB, and the transcriptional activation signal for SST-14 is absent even if Mechanism 1 were resolved. | CD26 blockade (adenosine) and persistent gut-derived opioid peptide load (mu-opioid) — two mechanistically distinct receptor inputs. Both are bypassed by forskolin, which activates adenylyl cyclase at its catalytic subunit independently of upstream receptor status. |
These two mechanisms operate independently and simultaneously. This is the mechanistic explanation for why single-target interventions have historically produced transient benefits followed by plateau — resolving one suppression mechanism while the other remains fully active creates a ceiling effect at whatever the unresolved mechanism permits.
SST-14 interneurons normally exert anti-inflammatory inhibitory tone on microglia and reactive astrocytes. When SST-14 output falls below functional threshold, that inhibitory tone is lost. Microglial reactivity increases, cytokine levels rise, IDO1 activates harder, quinolinic acid production increases, and excitotoxic pressure on remaining SST-14 interneurons intensifies. The system cannot self-correct because the correction mechanism has been disabled. This self-reinforcing latch explains why IDA tends to persist and deepen rather than spontaneously resolving, and why the protocol requires months of sustained multi-angle intervention rather than acute pharmacological correction.
The implication for trial design is direct: the adjunct protocol must be established for two to four months before IMIG initiation to build the metabolic infrastructure that SST-14 interneurons require to respond. A protocol that starts IMIG and supplements simultaneously does not test the infrastructure-preparation hypothesis — it tests concurrent combination only. The recommended sequencing (Section 10) establishes the adjunct cascade two months before IMIG initiation to enable both tests within the trial window.
Autism spectrum disorder affects males at approximately four times the rate of females. Four linked papers spanning 1986 to 2003 provide a specific and testable molecular explanation grounded in the same cAMP-CREB-SST-14 axis central to this framework.
Montminy et al. (PNAS 1986, PMID 2875459) identified the cyclic-AMP response element (CRE; 5′-TGACGTCA-3′) in the somatostatin gene promoter — the regulatory site through which cAMP drives SST-14 gene transcription, and which NF-κB blocks in IDA. Aronica et al. (PNAS 1994, PMID 8078914) established that estradiol activates membrane adenylyl cyclase nongenomically at physiological concentrations (half-maximal at 10 pM), generating cAMP sufficient to drive CRE-mediated transcription. Qiu, Rønnekleiv, and Kelly et al. (J Neuroscience 2003, PMID 14573532) characterized the complete intermediate signaling chain in hypothalamic neurons by single-cell RT-PCR: Gq-mER → Gαq → PLC → DAG → PKCδ → adenylyl cyclase VII → cAMP → PKA → CREB phosphorylation. The Gq-mER is pharmacologically distinct from nuclear ERα and ERβ, established using the selective STX ligand.
A female carrying equivalent upstream cascade burden retains a degree of SST-14 expression through this Gq-mER compensatory pathway that a prepubertal male cannot access. At puberty, testosterone-to-estradiol conversion through brain aromatase provides males with their first access to this pathway, consistent with the partial spontaneous improvement in social function observed in some adolescent males with IDA.
Practical implication for the trial: sex and pubertal status should be recorded as stratification variables. Post-pubertal males who have gained aromatase access to the Gq-mER pathway represent a cohort where the combination of endogenous estrogenic cAMP compensation plus forskolin's direct adenylyl cyclase activation may produce particularly strong synergistic cAMP output and faster response trajectories.
The founding conditions described above are common across the general pediatric population. Most children exposed to them do not develop IDA. The reason is constitutional biology: the genetically and immunologically determined capacity at each cascade step to absorb an environmental load before that step fails. Seven tipping points determine whether the same environmental insult propagates the full cascade or is absorbed without consequence.
| TP | Constitutional Factor | Clinical Relevance to Protocol | Evidence Level |
|---|---|---|---|
| TP1 Gastric Acid Capacity | ATP4A/ATP4B proton pump variants; CA2 carbonic anhydrase; SLC30A zinc transporters | Determines whether pH elevation reaches the pepsin-inactivation threshold. | L2 mechanism; L4 ASD-specific |
| TP2 CD26/DPP-IV Adenosine Clearance | Constitutively reduced DPP-IV enzymatic efficiency (Bashir & Al-Ayadhi 2014; EL-Alameey 2018) | Patients with constitutively low DPP-IV have no headroom when casomorphin, streptokinase, and mercury simultaneously block remaining capacity. Hydroxo-B12 and folinic acid address downstream SAH accumulation; forskolin bypasses the adenosine-adenylyl cyclase blockade directly. | L2 published DPP-IV reduction in ASD |
| TP3 Methylation Cycle Reserve | MTHFR C677T; MTRR; AHCY; folate receptor antibodies | Triple bottleneck — MTHFR C677T + folate receptor antibodies + adenosine accumulation produces methylation collapse from three independent directions. Hydroxo-B12 + folinic acid bypass this without methyl donor risk. | L1 methylation endophenotype (James 2004/2006) |
| TP4 Inflammatory Resolution Capacity | ALOX5/ALOX12/ALOX15 variants reducing SPM production; TLR4 variants | Most novel tipping point (Level 4 ASD-specific). ALOX variant-impaired individuals cannot resolve LPS-driven inflammation acutely. Omega-3 EPA/DHA provides SPM substrate for active inflammatory resolution — not generalized anti-inflammatory suppression. | L2 animal models; L4 ASD-specific |
| TP5 Kynurenine/QUIN Ratio Bias | KMO rs2275163, rs1053230 variants biasing toward excitotoxic QUIN branch | Patients with KMO variants reach the excitotoxic SST-14 threshold at lower IDO1 activation levels. NMN/NR addresses the NAD⁺ depletion from QUIN overproduction; K:T ratio identifies current IDO1 activation status. | L1 QUIN/KYNA shift in ASD; L2 KMO variants neuropsychiatric |
| TP6 Mitochondrial Buffering Reserve | GPX1, GSTM1, SOD2 antioxidant variants; mitochondrial reserve capacity (Frye et al. 2014) | Determines the State 1/State 2 boundary at equivalent cascade burden. NAC + sulforaphane address this oxidative vulnerability directly; NMN/NR supports mitochondrial ATP production for tonically active SST-14 interneurons. | L1 mitochondrial dysfunction in ASD |
| TP7 HLA-Mediated Autoantibody Susceptibility | HLA-DRB1, HLA-DQ alleles; CTLA4, PTPN22 | Determines whether molecular mimicry from casomorphin, streptokinase, or mercury-modified self-proteins generates autoantibodies against SST-14 interneuron surface proteins. IMIG's primary mechanism addresses this tipping point most directly. | L2 molecular mimicry; L3 CD26 autoantibodies in ASD |
The protocol is most appropriate for patients in the IDA biomarker-defined subgroup. The biomarker panel used for enrollment and comparator-arm stratification is detailed in Section 10.2.
The SST-14 Restoration white paper identifies two independent mechanisms that simultaneously silence SST-14 gene transcription in IDA:
Mechanism 1 — NF-κB-mediated CREB suppression. Chronic pro-inflammatory cytokines activate NF-κB, which competes with CREB for the co-activator CBP (CREB-binding protein). CBP is present in limited quantities and cannot be rapidly upregulated. NF-κB wins this competition under chronic inflammatory conditions, redirecting CBP to the inflammatory transcriptional program. Without CBP, CREB cannot open the CRE lock on the somatostatin gene promoter. Simultaneously, NF-κB recruits HDAC enzymes to compact the chromatin around the CRE, making the lock physically harder to reach.
Mechanism 2 — Gi-coupled adenylyl cyclase suppression, two independent inputs. Casomorphin and gliadorphin block the CD26 receptor where adenosine deaminase docks, preventing adenosine clearance (Input A). Accumulated adenosine activates inhibitory Gαi-coupled A1/A2A receptors on SST-14 interneurons, suppressing adenylyl cyclase. Independently, casomorphin and gliadorphin also bind directly to Gi-coupled mu-opioid receptors on SST-14 interneurons (Input B) — DAMGO EC50 ~30 nM, 25–60% adenylyl cyclase inhibition — present as long as opioid peptide load persists in circulation, regardless of adenosine clearance status. The two Gi inputs are additive: adenosine clearance support alone is insufficient to fully restore cAMP output while gut-derived opioid peptide load persists. Less adenylyl cyclase activity means less cAMP; less cAMP means PKA cannot phosphorylate CREB; unphosphorylated CREB cannot bind the CRE or recruit CBP even if CBP were available.
These two mechanisms operate independently and simultaneously. This is critical to understanding why single-target interventions have historically produced transient benefits that plateau — pushing through one locked door while the other remains locked from an entirely different direction, or from two different directions in the case of Mechanism 2's dual Gi inputs.
IMIG works upstream of both suppression mechanisms through immune modulation. Passive transfer of regulatory antibodies dampens NK cell and T-cell overactivation, reducing the pro-inflammatory cytokine production that drives NF-κB activation (Mechanism 1 relief from upstream). FcγRIIB upregulation reduces IL-6, TNF-α, and IFN-γ — the cytokines that activate IDO1, maintaining tryptophan depletion and NAD⁺ insufficiency. Reduction in autoantibody-mediated receptor disruption at neuronal surfaces may partially restore G-protein coupling efficiency, improving adenylyl cyclase responsiveness (indirect relief of Mechanism 2's adenosine input).
IMIG's power is that it addresses the root cause of Mechanism 1 directly — the chronic immune activation that sustains NF-κB. It works from the top down. What IMIG cannot reach directly is Mechanism 2's mu-opioid Gi input, the CD38-mediated NAD⁺ drain, or the SASP cytokine burden from senescent cells — dimensions of the suppression cascade that operate independently of active immune dysregulation. The adjunct cascade works from the bottom up and laterally, targeting these and other downstream nodes of both mechanisms simultaneously. Together they provide convergent multi-angle attack on the same final target.
The protocol targets both suppression mechanisms through eleven agents organized into three sequential phases. Phase 1 establishes a foundational anti-inflammatory, antioxidant, and metabolic floor across six agents administered concurrently. Phase 2 restores the NAD⁺/cAMP axis. Phase 3 delivers the direct cAMP push and senolytic clearance. IMIG readiness is assessed by biomarker gate (serum TNF and IL-6 trending toward normative range) after a minimum of eight weeks of continuous luteolin administration, typically placing IMIG initiation in or shortly after Phase 3.
Six agents administered concurrently from the opening of the priming period — an exception to single-compound sequencing discipline, justified by their mechanistically non-overlapping primary targets and shared objective of establishing a stable foundation before any agent that depends on that foundation is introduced.
Sulforaphane activates the Nrf2/Keap1 pathway and inhibits NF-κB through two independent routes: IKK-β suppression via the HO-1/CO pathway, and direct cysteine modification of the p65 subunit that reduces its DNA-binding affinity independently of IκB status — crossing the blood-brain barrier at therapeutically relevant concentrations. Singh et al. (PNAS 2014, n=44 RCT) demonstrated significant improvements in SRS and ABC scores.
N-Acetylcysteine (NAC) is a direct precursor to glutathione (GSH), the primary endogenous antioxidant and detoxification molecule. Reduced GSH and elevated GSSG ratios are documented across multiple ASD cohorts. Without adequate glutathione to buffer ROS, NF-κB suppression from other agents fights against ongoing ROS-driven reactivation — NAC operates upstream of every subsequent agent in the sequence. It additionally normalizes system xCT (cystine-glutamate antiporter) activity, reducing the glutamate efflux that feeds excitotoxic receptor stimulation, and is of particular benefit in the GSTM1/GSTT1-null genotypes overrepresented in ASD.
Hydroxocobalamin + Folinic Acid addresses MTRR methylation cycle impairment contributing to adenosine accumulation through the SAH pathway. In COMT Val158Met carriers, hydroxocobalamin/folinic acid is the mandatory form — methylcobalamin is contraindicated in this genotype.
Omega-3 Fatty Acids (EPA/DHA) serve a dual role: substrate for active resolution of neuroinflammation and structural constituents of neuronal membranes whose integrity is prerequisite for the receptor signaling the protocol restores. EPA and DHA convert to specialized pro-resolving mediators (SPMs) via the ALOX and COX-2 pathways, actively terminating inflammatory cascades. DHA-derived neuroprotectin D1 (NPD1) suppresses microglial NF-κB via a route distinct from luteolin's and sulforaphane's mechanisms — a fourth independent entry point into NF-κB suppression. Membrane DHA incorporation during Phase 1 also prepares the lipid environment for enhanced adenylyl cyclase catalytic response ahead of Phase 3.
Tributyrin is a stable, lipid-encapsulated delivery vehicle for butyric acid. Colonocytes derive roughly 70% of their energy from butyrate oxidation; deficiency from gut dysbiosis impairs tight junction maintenance, allowing LPS translocation into systemic circulation. Butyrate upregulates tight junction proteins (claudin-1, occludin, ZO-1) through HDAC inhibition, and this same HDAC inhibition prevents deacetylase-mediated removal of the acetyl mark required for NF-κB p65's maximal transcriptional activity — a fifth independent entry point into NF-κB suppression. Tributyrin does no harm across any genomic profile, making it a consistent biological floor across all participants.
Magnesium Glycinate is a physiologically precise modulator of NMDA receptor-mediated excitotoxicity and mitochondrial bioenergetic failure — not a supplementary micronutrient. At resting membrane potential, magnesium physically blocks the NMDA receptor channel pore against calcium and sodium influx; the neuroinflammatory environment's combination of elevated glutamate and reduced membrane polarization relieves this block, and magnesium repletion restores it. Magnesium also inhibits the HPA axis at multiple levels, reducing CRH, ACTH, and cortisol output — relevant given that CRH levels do not normalize with luteolin treatment alone. Magnesium deficiency is among the most consistently documented nutritional findings in the ASD population.
Introduced after one month of reduced inflammatory burden, when IDO1 has been partially suppressed and NAD⁺ salvage pathway conversion efficiency has improved.
Luteolin (Liposomal) provides the most proximal available NF-κB suppression point — stabilizing IκB against phosphorylation and blocking NF-κB nuclear translocation before it occurs. It stabilizes mast cells, drives microglial M1→M2 polarization, provides partial PDE4 inhibition extending cAMP half-life ahead of Phase 3, and inhibits CD38 — the NADase that otherwise drains the NAD⁺ pool NMN is restoring in parallel this same month. A proposed additional role in SPARC suppression supporting the A1→A2 astrocyte transition is mechanistically plausible by extrapolation from luteolin's general anti-inflammatory profile, but is not yet confirmed by primary literature specific to luteolin and SPARC.
NMN (Liposomal) restores the NAD⁺ pool depleted by IDO1-driven tryptophan diversion and CD38 overconsumption. NAD⁺ is both the substrate for mitochondrial ATP synthesis and the coenzyme for SIRT1, which deacetylates NF-κB's p65 subunit at lysine 310 — the specific acetylation site required for p65's maximal transcriptional activity. NAD⁺ is also the substrate for ATP, which adenylyl cyclase converts to cAMP, so NMN supports adenylyl cyclase function directly, not only mitochondrial respiration. Administered concurrently with luteolin so CD38 inhibition and NAD⁺ repletion arrive together.
Arrives into an environment where two months of Phase 1 and 2 agents have lowered NF-κB occupancy of the CRE site to its lowest point since cascade onset, and IMIG readiness assessment typically begins here.
Forskolin (Standardized) directly activates adenylyl cyclase by binding its catalytic subunit, driving cAMP synthesis independently of upstream receptor status — bypassing both Gi inputs to Mechanism 2 simultaneously (adenosine A1/A2A receptor blockade and mu-opioid receptor suppression). Adenylyl cyclase isoforms AC1, AC2, AC5, AC7, and AC8 are all forskolin-sensitive. Dosing must be genomically individualized by COMT status under clinical supervision; forskolin is contraindicated in hyperthyroid or cardiac patients.
On the dose itself. This protocol's forskolin ceiling is substantially lower than commercial forskolin products marketed for weight loss and bodybuilding, which are dosed for adipocyte lipolysis — a completely different endpoint. This protocol is not using a smaller version of that same intervention. It is targeting a different and far more sensitive endpoint — precise cAMP activation in SST-14 interneurons in a pediatric neurological population — genotype-stratified by COMT status and set deliberately low rather than under-dosed. A parent or clinician encountering standard commercial forskolin dosing elsewhere should not read that as the applicable reference point here. The specific dose is determined individually with the treating clinician, not from this page.
Fisetin (Liposomal), administered concurrently with forskolin, selectively clears senescent cells accumulated from chronic inflammatory burden. Senescent cells secrete the senescence-associated secretory phenotype (SASP) — IL-6, IL-1β, TNF-α — maintaining chronic NF-κB and IDO1 activation independently of active immune dysregulation that IMIG addresses. Fisetin also activates SIRT1 and drives BDNF/CREB upregulation. Yousefzadeh et al. (2018) identified fisetin as the most potent senolytic flavonoid tested.
Palmitoylethanolamide (PEA) is the one agent with a genuinely strong mechanistic and clinical case that is deliberately excluded from the current protocol, rather than omitted for lack of evidence. PEA is an endogenous lipid signaling molecule found at reduced levels in the ASD population, with downregulated receptor expression documented alongside it. Its principal action is activation of PPAR-α, a nuclear receptor that suppresses NF-κB-driven cytokine transcription through a mechanism entirely distinct from every agent already in the protocol — sulforaphane's IKK-β/p65 route, luteolin's IκB stabilization, omega-3's NPD1 pathway, and tributyrin's HDAC-dependent route. This makes PEA a seventh independent NF-κB suppression entry point, beyond the six the current eleven-agent architecture already covers. PEA also modulates CB2, GPR55, and TRPV1 receptors through enhanced endocannabinoid system tone, without direct CB1 activity. A randomized, double-blind, placebo-controlled trial found PEA added to risperidone outperformed risperidone alone for ASD-associated irritability and hyperactivity, with a substantial effect size.
PEA is deferred rather than included because its mechanism runs through the endocannabinoid system broadly, and three genetic variants interact with that system in ways not yet mapped in this population: reduced PEA breakdown capacity in one variant, altered CB1-mediated dopaminergic modulation in combination with COMT status, and further individual variation from a third variant whose interaction risk in the ASD genomic landscape is not yet adequately characterized. This is a genomic-characterization gap, not a failure of the compound — the evidence for PEA itself is arguably stronger than for some agents already included. What would resolve it is a specific, tractable piece of research: a genomic association study of these three variant loci in the immune-derived ASD subgroup, combined with pharmacokinetic study of PEA levels across the relevant genotype range. That data would define safe use across the population and support PEA's inclusion in a future protocol iteration. Until then, PEA sits outside the standardized three-phase sequence, with individual use a matter for the treating clinician following full genomic review — not something this page specifies.
The protocol is not a simultaneous supplement stack. It is a staged biological preparation in which each phase creates better conditions for the next, reflecting four cascade-level dependencies: antioxidant foundation before NAD⁺ repletion (PARP competition avoidance); inflammatory environment reduction before cAMP restoration (NF-κB/CBP competition relief); mitochondrial preparation before transcriptional activation (energetic capacity for interneuron response); and membrane DHA incorporation before direct adenylyl cyclase activation (lipid environment enhancement of catalytic response).
A note on scope: this page now reflects the full eleven-agent, three-phase protocol structure, developed in collaboration with the clinical PI. Earlier versions of this page presented a simplified five-agent, five-month representative account; this version reflects the complete protocol.
The adjunct cascade and IMIG are not competing therapeutic strategies. They are convergent interventions that attack the same two suppression mechanisms from opposite directions simultaneously. When both are running, every node of the suppression is being addressed from at least two independent directions at once — and some nodes only by the cascade.
| Suppression Node | IMIG Pathway | Adjunct Cascade Pathway | Cascade Advantage Over IMIG Alone |
|---|---|---|---|
| NF-κB occupancy of CRE site (Mechanism 1) | Reduces cytokine load driving NF-κB nuclear translocation from upstream — autoantibody clearance, NK cell modulation, cytokine dampening. | Sulforaphane (IKK-β) + Luteolin (AP-1) + Fisetin (SASP senolytic) + NMN/NR-driven SIRT1 (p65 deacetylation). Suppresses NF-κB signal transduction independently of cytokine source. | Four independent NF-κB suppression mechanisms vs. IMIG's single upstream route. The SASP driver addressed by fisetin is inaccessible to IMIG. |
| Adenylyl cyclase suppression — adenosine Gi input (Mechanism 2A) | Indirectly: reduces IDO1 activation from lower cytokine load, partially restoring the tryptophan-to-NAD⁺ pathway and reducing adenosine accumulation over weeks to months. | NMN/NR restores NAD⁺ substrate (and thereby ATP, the adenylyl cyclase substrate); Luteolin/CD38 inhibition plugs the NAD⁺ drain. Forskolin bypasses adenosine receptor suppression entirely at the catalytic subunit. | More direct and faster acting on adenosine-AC suppression than IMIG's indirect route. Forskolin bypasses the receptor entirely. |
| Adenylyl cyclase suppression — mu-opioid Gi input (Mechanism 2B) | Indirectly: reduced immune activation may partially reduce gut permeability and casomorphin load over time. | Forskolin directly activates adenylyl cyclase at the catalytic subunit, bypassing mu-opioid Gi suppression completely regardless of circulating opioid peptide levels. | IMIG has no direct mechanism on the mu-opioid Gi input. Forskolin bypasses it completely — a mechanism unique to the adjunct cascade. |
| SASP cytokine background (independent NF-κB driver) | Cannot directly clear senescent cells; autoantibody and cytokine modulation does not address SASP-independent NF-κB from accumulated senescent cells. | Fisetin senolytic clearance reduces the SASP cytokine background that maintains NF-κB independently of active immune dysregulation. | Unique cascade advantage — IMIG cannot reach this node. |
| A1→A2 astrocyte plasticity transition | Indirectly: reducing microglial M1 activation from lower cytokine load creates a more permissive environment for the A1→A2 shift. | Luteolin is proposed to suppress SPARC expression, based on its general anti-inflammatory action — a mechanistically plausible but not yet primary-literature-confirmed link specific to SPARC. Sulforaphane reduces microglial M1 polarization. Liddelow et al. (Nature 2017) established A1 polarization as a maintained, reversible state. | Cascade addresses this more directly — IMIG removes the driving signal; luteolin's proposed SPARC action would suppress the maintaining signal from a second direction, pending confirmation. |
| SST-14 interneuron metabolic substrate | Indirectly: reduced IDO1 activation partially restores the tryptophan-to-NAD⁺ pathway. Explicitly stated in the SST-14 Restoration white paper as requiring adjunct metabolic support for State 2 patients. | NMN directly restores NAD⁺ for tonic firing; magnesium glycinate buffers NMDA-mediated excitotoxic pressure on the interneuron; NAC and sulforaphane protect against oxidative stress; omega-3-derived SPMs support membrane integrity for receptor signaling. | Cascade addresses this dimension more completely than IMIG alone. |
Scientific integrity requires stating the differences clearly. The adjunct cascade is a convergent mechanism — it is not equivalent to IMIG, and there are specific capabilities that immunoglobulin therapy provides that no supplement combination can replicate:
The optimal combination. IMIG addresses what supplements cannot: autoantibody clearance and rapid broad-spectrum immune modulation. The adjunct cascade addresses what IMIG does not directly target: the mu-opioid Gi bypass via forskolin, the CD38 NAD⁺ drain, the SASP senolytic burden, and direct A1→A2 astrocyte plasticity restoration. Used together, IMIG removes the transcriptional ceiling while the adjunct cascade builds the metabolic floor. The cohort split (Section 10) tests this complementarity hypothesis directly.
The proposed design allocates enrolled IDA-biomarker-confirmed participants to two cohorts: IMIG alone (Cohort A) and IMIG plus the adjunct protocol (Cohort B). Both cohorts receive IMIG on the standard dosing schedule. The primary endpoint is identical for both — neuropeptide cascade biomarker restoration and functional domain assessment. The secondary endpoint is response trajectory: time to first measurable biomarker improvement and slope of biomarker change at three, six, and twelve months.
| Phase | Cohort A (IMIG Alone) | Cohort B (IMIG + Priming Protocol) | Purpose |
|---|---|---|---|
| Month 1 (Pre-IMIG) | Baseline biomarker panel. No intervention. | Begin all six Phase 1 agents concurrently: NAC, sulforaphane, hydroxo-B12 + folinic acid, omega-3, tributyrin, magnesium glycinate. Order priority lab panel: K:T ratio, L:P ratio, NK/lymphocyte subset, Cunningham Panel, MMA, homocysteine. | Establish the foundational anti-inflammatory, antioxidant, and metabolic floor before IMIG initiation. Baseline biomarker comparison point for both cohorts. |
| Month 2 (Pre-IMIG) | Continued observation. | Add Phase 2: luteolin (liposomal) + NMN (liposomal), concurrent. Two NF-κB suppression mechanisms now running alongside CD38/NAD⁺ restoration. | NAD⁺/cAMP axis restoration underway. Cellular environment meaningfully improved from Month 1 baseline. |
| Month 3 (IMIG readiness assessment) | IMIG candidacy evaluation. | Add Phase 3: forskolin + fisetin (liposomal), concurrent. IMIG readiness assessed by biomarker gate — serum TNF and IL-6 trending toward normative range — after a minimum of 8 weeks of continuous luteolin. | Full eleven-agent foundation in place. IMIG initiation is biomarker-gated, not fixed to a calendar month, for both cohorts. |
| Month 3–4 (IMIG initiation) | IMIG initiated once biomarker gate is met. Standard clinical monitoring. | Continue full three-phase protocol. Initiate IMIG once biomarker gate is met, typically shortly after Phase 3 begins. | First point at which both cohorts receive IMIG. Fisetin's SASP clearance and forskolin's dual Gi bypass are already running by this point in Cohort B. |
| Months 5–12 | Continue IMIG. Biomarker and functional assessments at 6 and 12 months. | Continue full protocol and IMIG. Biomarker and functional assessments at 6 and 12 months alongside Cohort A. | Primary endpoint comparison. Response trajectory analysis. Durability assessment. |
| Biomarker | Threshold / Method | What It Measures | Frequency |
|---|---|---|---|
| Plasma kynurenine:tryptophan (K:T) ratio | Elevated relative to age-matched reference range (HPLC-MS/MS method) | Active IDO1-driven tryptophan diversion. Primary marker of inflammatory cascade activity. | Baseline; Month 5; Month 12 |
| Cytokine panel (IL-1β, IL-6, TNF-α) | Elevated relative to age-matched reference range | NF-κB-activating inflammatory load suppressing CREB at the somatostatin gene CRE. | Baseline; Month 5; Month 12 |
| Cunningham Panel (neural autoantibodies) | Positive per standard clinical laboratory interpretation | Autoantibody-mediated State 1 silencing. Primary IMIG pathway predictor. | Baseline; Month 12 |
| Lactate:pyruvate ratio | Elevated relative to standard clinical reference range | State 2 metabolic exhaustion. Determines NMN urgency. | Baseline; Month 6 |
| Plasma quinolinic acid (QUIN) | Elevated vs. age-matched controls | Direct excitotoxic driver of SST-14 metabolic stress. Informs NMN sequencing. | Baseline; Month 5; Month 12 |
| Homocysteine | Elevated relative to standard clinical reference range | CD26-driven methionine synthase rate-limitation and methylation cycle failure. | Baseline; Month 6 |
| NK/lymphocyte subset panel | Standard clinical reference ranges | NK cell activation status. IMIG mechanism validation. | Baseline; Month 5; Month 12 |
The cohort-split proposal raises two independent questions that can be evaluated separately:
| Question | What It Asks | Independent Evaluation |
|---|---|---|
| 1. Scientific | Does the mechanistic rationale hold? Are the compounds, sequencing, and convergence argument sufficiently grounded to justify inclusion in a clinical protocol alongside IMIG? | Can be evaluated on the mechanistic evidence presented in this document, independently of trial logistics. |
| 2. Trial Design | Is a split cohort feasible within the CDMRP trial architecture — half IMIG alone, half IMIG + adjunct — without compromising the primary endpoint or the sample size calculation? | Requires assessment of protocol complexity, cost, CDMRP review criteria, and statistical power. Independent of the scientific question. |
A positive answer to Question 1 and a negative to Question 2 would still support incorporating the adjunct protocol as a required companion recommendation in the trial's standard-of-care documentation — even if the formal split cohort design is not feasible within the CDMRP architecture.
If the adjunct cascade and IMIG together are producing meaningful SST-14 transcriptional restoration, the following functional signals would be expected over a 3–12 month trajectory. These are the same signals expected from IMIG alone — because the final molecular target is the same. The comparator question is whether Cohort B shows faster onset or greater magnitude.
Sleep architecture improvement (typically earliest — 8–16 weeks). SST-14 interneurons contribute to NREM slow-wave sleep generation through their role in VIP-mediated cortical disinhibition. Improved sleep quality, consolidation, and night-waking reduction are often the earliest observable functional signals of partial SST-14 restoration.
Gastrointestinal motility improvement (8–20 weeks). VIP is a key enteric neurotransmitter — its upstream coordination through SST-14 output affects gut motility, secretion timing, and mucosal immune tone. Improvements in constipation regularity, stool consistency, and post-meal discomfort reflect partial VIP cascade restoration.
Sensory processing shifts (12–24 weeks). SST-14 interneurons gate long-range thalamocortical inputs at pyramidal neuron distal dendrites — controlling the signal-to-noise ratio of sensory integration. Reduced sensory defensiveness, improved tolerance of previously aversive stimuli, and less sensory-seeking behavior reflect partial restoration of this gating function.
Social engagement and communicative spontaneity (16–40 weeks). These improvements are typically later-emerging because they depend on coordinated oxytocin pulsatility restoration in response to genuine social stimuli — a more complex downstream output requiring more complete SST-14 interneuron recovery. Earlier social improvements often manifest as reduced anxiety in social contexts before active social engagement increases.
The absence of these signals after a well-implemented 6-month protocol should prompt biomarker reassessment — checking whether the K:T ratio and cytokine panel have moved, whether homocysteine has normalized, and whether the Cunningham Panel autoantibodies have changed. If biomarkers have not moved, the upstream driving conditions remain active and the protocol is operating against an unaddressed source.
The SST-14 transcriptional suppression problem in immune-derived autism has two independent mechanisms. IMIG addresses both through upstream immune modulation — clearing the autoantibody and cytokine load that drives NF-κB/CREB competition at the somatostatin gene promoter and, indirectly, the Gi-mediated adenylyl cyclase suppression that prevents cAMP production. IMIG works from the top down and represents the most powerful single upstream intervention available within the current evidence base.
The adjunct cascade addresses both mechanisms through convergent bottom-up and lateral interventions: sulforaphane and luteolin attacking NF-κB from two independent molecular angles; NMN/NR and luteolin-CD38 inhibition restoring the NAD⁺/cAMP substrate axis; fisetin clearing the SASP cytokine burden that maintains the biological latch independently of active immune dysregulation; and forskolin directly activating adenylyl cyclase at the catalytic subunit, bypassing both the adenosine A1/A2A and mu-opioid Gi receptor inputs to Mechanism 2 simultaneously — a dual bypass that IMIG cannot provide.
The adjunct cascade is not a substitute for IMIG where IMIG is indicated. It is a mechanistically grounded companion that addresses dimensions of the suppression cascade that IMIG cannot reach directly, and it builds the metabolic floor that SST-14 interneurons require to respond when the transcriptional ceiling is lifted.
Formal Recommendation. This document recommends that the adjunct metabolic protocol — as sequenced in Section 7 and mechanistically justified in Sections 6 and 8 — be evaluated for inclusion as a structured comparator arm in the proposed IMIG clinical trial for immune-derived autism. The proposed design allocates half the enrolled cohort to IMIG alone and half to IMIG plus the adjunct protocol, with neuropeptide cascade biomarkers as the primary comparative endpoint (Section 10). A positive result establishes the first evidence base for the adjunct protocol as a clinical intervention and provides the foundation for a dedicated standalone trial. A negative result provides equally important evidence that upstream immune clearance is the rate-limiting step and supplements cannot meaningfully accelerate the response trajectory. Either result advances the field.
This document is submitted for scientific evaluation and collaborative trial design discussion. All claims are evidence-level annotated. The authors welcome critique of the mechanistic reasoning, the compound selection, the sequencing logic, and the proposed trial architecture.
Medical Disclaimer: This document presents a mechanistic hypothesis for scientific discussion and collaborative trial design evaluation. It does not constitute medical advice, a treatment protocol, or a clinical recommendation. All therapeutic decisions must be made by licensed clinicians with direct knowledge of the patient. The adjunct protocol described here has not been evaluated in a controlled clinical trial. Large-scale validation studies are required before any component of this framework can be considered established clinical practice.